BACKGROUND: Serum Procalcitonin (PCT) is a biomarker that is frequently used to diagnose an infection. In some cases of thoracic malignancy, procalcitonin level appears to increase. However, the role of procalcitonin to diagnose malignancy is not certain yet, and the causes have not been known. AIM: This study aimed to investigate procalcitonin levels in non-small cell lung cancer patients. METHODS: This was an observational study with a cross-sectional design. All lung cancer patients did not diagnose based on cytology/histopathology results with no evidence nor were signs and symptoms of infection recruited through consecutive sampling. The subtypes of lung cancer include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, staged III and IV. The procalcitonin levels were analysed from blood using immunofluorescent assay. Data were then analysed with the Chi-Square test by Epi Info™ 7 programs in which p-value < 0.05 was considered statistically significant. RESULTS: A total of 68 lung cancer patients fulfilled the criteria of this study, 55 men (80.9%) and 13 women (19.1%). The highest percentage of cytology/histopathology type found was adenocarcinoma (80.9%), and 60.3% of those were diagnosed in stage IV. An increased procalcitonin level (greater than 0.01 ng/mL) occurred in 80.9% of Non-Small Cell Lung Cancer (NSCLC) patients. It appears that the higher the stage of lung cancer, the lower procalcitonin levels would be, although it was not statistically significant. There was no association between lung cancer subtype with procalcitonin levels. CONCLUSION: An increased level of procalcitonin may be an indication not only for infection but also for Non-Small Cell Lung Cancer.
16 December 2018 in Open Access Macedonian Journal of Medical Sciences
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) exhibit persistent dyspnea in daily activities and irreversible airflow obstruction. These will finally lead to an inability to carry on daily activities and markedly decrease their quality of life. Endurance training was considered as therapy modality to alleviate several symptoms experienced by COPD patients. AIM: This study aims to identify the impact of lower-limb exercise on dyspnea and spirometry test results in COPD patients. METHODS: We performed a quasi-experimental study in July 2017 on 20 stable COPD patients divided both in group C and D according to GOLD 2017 criteria. Patients were given an individualised dose of stationary cycling twice a week for one month in which every session lasted 5-20 minutes gradually. Before and after rehabilitation program, pulmonary function tests were measured by spirometry to obtain per cent predicted of Forced Expiratory Volume in 1 second (FEV1), Forced Volume Capacity (FVC), Peak Expiratory Flow (PEF) and Forced Expiratory Flow at 25-75% of the pulmonary volume (FEF25-75), and dyspnea was measured by the mMRC index. Statistical analysis was performed by Wilcoxon and T-dependent test. RESULTS: Baseline value of FVC (49.6 ± 21.6%) increased significantly to 59.65 ± 16.53% after one month of endurance training program (p = 0.01). Surprisingly, there was also a significant increase in FEV1 value from 46.9 ± 21.7 to 52.9 ± 20.7% (p < 0.005). The increase of FVC and FEV1 in group C was slightly higher than in group D although not statistically significant (p = 0.29; p = 0.25 respectively). However, no difference was observed in PEF and FEF25-75 value (p > 0.05). Patients’ dyspnea scale also showed significant improvement (p < 0.001) from mMRC median scale 2 (range 1-3) to 1 (range 0-2) in both groups C and D. There was no exacerbation found during rehabilitation program. CONCLUSION: Twice a week lower-limb endurance training for one-month improved dyspnea and pulmonary function test results in COPD patients safely and effectively.
Coronavirus disease 2019 (COVID-19) has been identified for more than two years, yet studies assessing post-infection lung function are limited. Reports on lung function in COVID-19 patients indicate that patients have restrictive defects and small airway dysfunction that can persist and are not necessarily related to the severity of the disease. The aim of this study was to assess the incidence of small airway obstruction and its incidence-associated factors among COVID-19 survivors to better describe the long-term effects of COVID-19. A cross-sectional study was conducted among COVID-19 survivors who less than 50 years at Medan Adventist Hospital between 2020–2022. The data were collected through interview, direct assessment and respiratory examination. A total of 89 COVID-19 survivors were recruited of which the majority of them were female with a mean age of 32.6-year-old with the largest group was 19–30 years. The comorbidities found among the survivors were heart and thyroid disorders, with the most common symptom of post-COVID-19 was fatigue. Most of them had mild COVID-19. The mean forced mid-expiratory flow (FEF25–75%) was 96.3±20.22, with an incidence rate of small airway obstruction was 19.1%. Univariate and multivariate analyses indicated no significant association between age, gender, comorbidities, history of oxygenation during COVID-19 treatment, COVID-19 severity and the type of post COVID-19 syndrome symptoms with the incidence of small airway obstruction. In conclusion, among COVID-19 survivors who were less than 50 years old, those studied variables seems have less association with the incidence of small airway obstruction. Nevertheless, a further study with a bigger sample size is important to be conducted.
Systemic inflammation in chronic obstructive pulmonary disease (COPD) contributes to multimorbidity and a diminished quality of life. Probiotics, through the gut-lung axis, have shown potential to mitigate systemic inflammation; however, their specific role in COPD-related inflammation remains unclear. The aim of this study was to evaluate the efficacy of probiotics in reducing serum interleukin-6 (IL-6) levels by enhancing butyric acid production in a murine model of COPD. An in vivo experimental study with a post-test-only control group design was conducted using 30 C57BL/6 mice randomized into five groups: non-COPD healthy control, untreated COPD, COPD treated with bronchodilator, COPD treated with probiotics, and COPD treated with a combination of bronchodilator and probiotics. COPD was induced by six weeks of cigarette smoke exposure, followed by six weeks of treatment while continuing the smoke exposure. Caecal butyric acid and serum IL-6 levels were measured using enzyme-linked immunosorbent assay (ELISA) and gas chromatography, respectively. Caecal butyric acid levels were lowest in untreated COPD mice (1.2±0.28 mmol/L) and significantly increased with probiotic administration (6.6±4.43 mmol/L, p=0.010), exceeding levels observed in healthy controls (3.9±2.05 mmol/L). Serum IL-6 levels were highest in COPD-induced mice (19.4±6.71 pg/mL) and significantly reduced with administration of probiotics (13.5±0.43 pg/mL, p=0.035), approaching levels of healthy controls (13.0±2.24 pg/mL, p=0.847). A negative correlation was observed between butyric acid and serum IL-6 levels (r=-0.420; p=0.021), suggesting that higher butyric acid levels were associated with reduced systemic inflammation. These findings demonstrated that probiotics, via their metabolite butyric acid, effectively reduced systemic inflammation in a COPD mouse model, highlighting their potential as a therapeutic approach for managing COPD-related inflammation.
1 January 2018 in International Journal of Surgery Case Reports
Primary mediastinal dedifferentiated liposarcoma is an extremely rare malignant mesenchymal neoplasm composed of lipogenic tissue. It can be huge enough to compress heart and surrounding organs leading to clinical symptoms. We present a case of huge primary mediastinal dedifferentiated liposarcoma in a 54-year-old man, confirmed by immunohistochemistry staining, who received surgical removal. However, six months later, the tumor recurred, and the patient underwent chemotherapy for 6 cycles resulting in stable disease. Six months after the last visit, the tumor showed no sign of recurrence anymore. Among the various subtypes, the dedifferentiated mediastinal liposarcoma is the least found type of liposarcoma and often leads to misdiagnosis. Challenges occurred not only in diagnosis but also in treatment since it frequently grows back and chemotherapy may be needed after surgery. This is a highly rare case of huge mediastinal liposarcoma that recurred after surgery and gave a satisfying outcome after chemotherapy.
29 August 2019 in Open Access Macedonian Journal of Medical Sciences
BACKGROUND: Lung cancer is the most frequently found cancer among men around the world and is is the main cause of cancer deaths. The occurrence of lung cancer is particularly associated with smoking habit around men, along with environmental tobacco smoke in the workplace. It is diagnosed in patients with the varied clinical and demographical profile. AIM: We aimed to determine the clinical profile of men with non-small cell lung cancer in Adam Malik Hospital Medan based on age, smoking habits, occupation, clinical symptoms, clinical stage, and type of lung cancer histopathology MATERIAL AND METHODS: This is a descriptive study using medical record from 2012 to 2015 of all men with non-small cell lung cancer at Adam Malik Hospital Medan, Indonesia RESULTS: Most men with lung cancer are aged 51-60 years old (43.5%) and work like entrepreneurs. More than 80% of men with lung cancer are heavy smokers. Adenocarcinoma is the most common type of lung cancer, and 2/3 of lung cancer patients are diagnosed at an advanced stage. CONCLUSION: Lung cancer occurs most often in active smokers in the age group above 50 years. The most dominant type of histopathology is adenocarcinoma and is frequently diagnosed in the late stages.